INDEMNIFICATION AGREEMENTIndemnification Agreement • December 19th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Delaware
CONVERTIBLE NOTE PURCHASE AGREEMENTConvertible Note Purchase Agreement • December 19th, 2016 • Stocosil Inc. • Pharmaceutical preparations • California
THIS CONVERTIBLE NOTE PURCHASE AGREEMENT (the “Agreement”) is made effective and dated for references purposes as of February _____, 2015 (the “Effective Date”), by and between Stocosil Inc., a Delaware corporation (the “Company”) and the investor whose name and signature are set forth on the signature page to this Agreement (the “Investor”).
ENGAGEMENT LETTEREngagement Letter • September 14th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Delaware
This engagement letter (the “Agreement”) confirms the terms upon which Stocosil Inc. (the “Client”) engages Monarch Bay Securities, LLC (“MBS”, the “Placement Agent”). MBS is engaged to act as the exclusive Placement Agent to the Client in connection with a Financing (as defined below) of securities on behalf of Client . MBS is also the “Financial Adviser,” which client hereby engages upon signing this letter.
ESCROW SERVICES AND CUSTODY AGREEMENTEscrow Services and Custody Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Virginia
This Escrow Services and Custody Agreement (this “Agreement”) is effective this 8th day of November, 2016 (the “Effective Date”) by and among Stocosil, Inc., a Delaware corporation (“Issuer”), and Folio Investments, Inc. (“Folio”), a Virginia corporation. Issuer and Folio are hereby referred to collectively as the “Parties” or individually as a “Party”.
CONSULTING & COORDINATION RETAINER AGREEMENT:Consulting & Coordination Retainer Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • California
Stocosil Inc., a Delaware corporation with an address of 17870 Castleton St., Ste. 250, City of Industry, CA 91765 (“Company”), is intending to engage in a public offering of securities pursuant to an exemption from registration pursuant to Section 3(b) of the Securities Act of 1933, as amended (the “Act”) and Regulation A+ promulgated thereunder (the “Offering”). Both parties may be hereinafter referred to each individually as a “Party” and collectively as the “Parties”. This Agreement supersedes and replaces any and all prior agreements between the parties.
MASTER SERVICES AGREEMENTMaster Services Agreement • December 19th, 2016 • Stocosil Inc. • Pharmaceutical preparations • California
This Master Services Agreement (“Agreement”) is entered into and dated as of May 1, 2015, by and between Stocosil Inc., a Delaware corporation (“Company”), and Autotelic Inc., a Delaware corporation (“Autotelic”). This Agreement is retroactive to the effective date of January 1, 2015.
SECOND AMENDED AND RESTATED ENGAGEMENT LETTEREngagement Letter • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Delaware
This second amended and restated engagement letter (the “Agreement”) confirms the terms upon which Stocosil Inc. (the “Client”) engages Boustead Securities, LLC (f/k/a Monarch Bay Securities, LLC) (“Boustead” or the “Placement Agent”). The Placement Agent is engaged to act as the exclusive placement agent to the Client in connection with a Financing (as defined below) of securities on behalf of the Client. The Placement Agent is also the “Financial Adviser,” which the Client hereby engages upon signing this Agreement. This Agreement amends, restates and supersedes in its entirety that certain Amended and Restated Engagement Letter dated September 19, 2016 between the Client and the Placement Agent (the “Original Letter”).
ISSUER CUSTODY AND SERVICES AGREEMENTIssuer Custody and Services Agreement • September 14th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Virginia
This Issuer Custody and Services Agreement (this “Agreement”) is effective this _____ day of ___________, 20___ (the “Effective Date”) by and among ___________________________(Company Name), a __________________ [Type of Corporate Entity and State of Establishment] (“Issuer”), and FOLIOfn Investments, Inc. (“Folio”), a Virginia corporation. Issuer and Folio are hereby referred to collectively as the “Parties” or individually as a “Party”.
PRODUCT DEVELOPMENT, LICENCE AND COMMERCIALIZATION AGREEMENTProduct Development, Licence and Commercialization Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations
This Product Development, Licence and Commercialization Agreement (“Agreement”) is made and entered into as of February 27th, 2015 by and between Daewoong Pharmaceuticals Co. Ltd. a company incorporated under the laws of South Korea and having its registered office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, Korea (“DAEWOONG”) and Autotelic, LLC and Autotelic, Inc., and Stocosil Inc. (“STOCOSIL”) companies incorporated under the laws of Delaware, having its registered office at 17870 Castleton Street, Ste. 250, City of Industry, CA 91748, USA. (“STOCOSIL”).
Addendum 1 to that Private Placement Platform Referral Agreement Exhibit A between FOLIOfn Investments, Inc. and Monarch Bay Securities, LLC of the 24th day of May, 2016Private Placement Platform Referral Agreement • September 14th, 2016 • Stocosil Inc. • Pharmaceutical preparations
This Private Placement Platform Referral Agreement Addendum is effective this 1st day of August, 2016 (the “Effective Date”) by and among Monarch Bay Securities, LLC, a California limited liability company, having its principal office at 898 N. Sepulveda, Suite 475, El Segundo CA 90245, (the “Referring Party”) and FOLIOfn Investments, Inc., a corporation of the Commonwealth of Virginia (hereinafter “Folio”) with its principal place of business at 8180 Greensboro Drive, 8th Floor, McLean, VA 22102.
